Lung Cancer
Conference Coverage
Gene test may offer insights into treatment response in advanced NSCLC
Researchers linked positive assay results to longer progression-free survival.
Feature
Cancer clinics begin to accommodate patients demanding new cancer detection tests
Sales teams are making a big push for multicancer early detection tests.
From the Journals
Over half of targetable NSCLC patients miss out on correct tx
For some patients it could mean missing the chance for long-term survival or even cure.
News
FDA rejects poziotinib for certain types of lung cancer
The clinical data the company submitted was deemed insufficient for approval.
Conference Coverage
Lung cancer screening pushes 20-year survival rate to 80%
Less than 6% of high-risk smokers get the recommended annual lung cancer screening.
Conference Coverage
Immunotherapeutic target could fill unmet need in NSCLC
Phase 2 clinical trial shows consistent benefits at all levels of PD-L1 expression.
From the Journals
Buzz kill: Lung damage looks worse in pot smokers
Emphysema was significantly more common among smokers (75%) than among nonsmokers, a new study finds.
Clinical Trials Track
Could your patient benefit? New trials in lung cancer
New lung cancer trials.
From the Journals
Durvalumab combinations show tentative promise in NSCLC
Phase 2 study indicates improved survival and objective response rate when combined with other immunotherapies.
From the Journals
Mutation burden predicts ICI response in lung cancer
Novel biomarker combined with PD-L1 expression could indicate selection of immunotherapy and avoid chemotherapy toxicities in some patients.